Wall Street brokerages expect Assembly Biosciences Inc (NASDAQ:ASMB) to post $3.21 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Assembly Biosciences’ earnings. The highest sales estimate is $3.22 million and the lowest is $3.20 million. Assembly Biosciences reported sales of $2.66 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 20.7%. The firm is scheduled to announce its next earnings report on Wednesday, November 7th.
According to Zacks, analysts expect that Assembly Biosciences will report full-year sales of $13.05 million for the current year, with estimates ranging from $12.00 million to $13.60 million. For the next financial year, analysts forecast that the company will report sales of $25.90 million, with estimates ranging from $12.87 million to $63.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Assembly Biosciences.
Assembly Biosciences (NASDAQ:ASMB) last issued its quarterly earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($1.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.42). Assembly Biosciences had a negative net margin of 457.20% and a negative return on equity of 66.34%. The business had revenue of $3.22 million for the quarter, compared to analysts’ expectations of $3.30 million.
A number of brokerages recently issued reports on ASMB. Zacks Investment Research raised shares of Assembly Biosciences from a “sell” rating to a “hold” rating in a research report on Tuesday. B. Riley raised shares of Assembly Biosciences from a “neutral” rating to a “buy” rating and set a $42.00 price target for the company in a research report on Monday, October 8th. ValuEngine cut shares of Assembly Biosciences from a “buy” rating to a “hold” rating in a research report on Wednesday, October 3rd. Robert W. Baird began coverage on shares of Assembly Biosciences in a research report on Wednesday, August 8th. They set an “outperform” rating and a $74.00 price target for the company. Finally, BidaskClub cut shares of Assembly Biosciences from a “sell” rating to a “strong sell” rating in a research report on Friday, July 13th. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $62.60.
In other Assembly Biosciences news, insider Uri A. Lopatin sold 15,540 shares of the firm’s stock in a transaction dated Thursday, September 6th. The shares were sold at an average price of $40.09, for a total transaction of $622,998.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Derek A. Small acquired 2,400 shares of Assembly Biosciences stock in a transaction on Thursday, July 19th. The shares were purchased at an average price of $41.48 per share, with a total value of $99,552.00. Following the completion of the purchase, the chief executive officer now owns 668,091 shares in the company, valued at approximately $27,712,414.68. The disclosure for this purchase can be found here. 18.20% of the stock is currently owned by company insiders.
A number of large investors have recently added to or reduced their stakes in ASMB. Bank of Montreal Can bought a new stake in Assembly Biosciences during the 2nd quarter valued at about $145,000. Quantbot Technologies LP bought a new stake in shares of Assembly Biosciences in the first quarter worth approximately $154,000. Jane Street Group LLC bought a new stake in shares of Assembly Biosciences in the first quarter worth approximately $204,000. MetLife Investment Advisors LLC bought a new stake in shares of Assembly Biosciences in the second quarter worth approximately $282,000. Finally, Quantitative Systematic Strategies LLC bought a new stake in shares of Assembly Biosciences in the second quarter worth approximately $348,000. Institutional investors and hedge funds own 65.21% of the company’s stock.
NASDAQ ASMB traded up $0.42 during trading hours on Wednesday, reaching $24.01. 215,867 shares of the company’s stock traded hands, compared to its average volume of 213,636. Assembly Biosciences has a 52-week low of $23.05 and a 52-week high of $67.36. The stock has a market cap of $945.08 million, a P/E ratio of -9.96 and a beta of 0.80.
Assembly Biosciences Company Profile
Assembly Biosciences, Inc operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States.
Featured Article: How to Use the New Google Finance Tool
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.